At Aequilibria Health we are developing a revolutionary digital platform to address a wide range of cognitive issues that can arise during ageing.
The detection of early signs of cognitive decline is crucial but awareness and actions are taken only at a late stage of the decline process.
Usually, the screening process is performed once or sparsely over time whilst diagnosis, treatment, and care plans would benefit from long-term monitoring.
Usually, the screening process is performed once or sparsely over time whilst diagnosis, treatment, and care plans would benefit from long-term monitoring.
Our main focus is addressing age-related cognitive decline providing digital tools that include effective assessment of cognitive decline and brain training in a way that can be available every day, in the comfort of people’s homes or workplaces, boosting effectivity, reliability and compliance.
Dementia affects 47 million people worldwide
(approx. 5% of the world’s elderly population) and predicted to increase to 75 million in 2030. 1 new case every 3 seconds
Dementia costs were estimated at $818 billion,
equivalent to 1.1% of GGDP*. By 2030, it is estimated to rise up to $ 2 trillion.
*Global Gross Domestic Product.
Dementia is underdiagnosed
If a diagnosis is made, it is typically at a late stage in the disease progression.
The team
Vincenzo Varriale, Dr., Ph.D.
Co-Director, Co-founder, Project Manager
Formerly researcher, University teacher and Chief Scientific Officer. His research topic focuses on psychometrics, cognitive performance and the neural correlates of intelligence. He has been the recipient of research grants, published numerous papers on high-IF journals and is co-owner of a US patent. He has a Master Degree in Psychology and a Ph.D. in Psychophysiology, both obtained at Sapienza University of Rome.
Emanuela Russo, Dr., Ph.D.
Co-founder, Clinical Consultant
Cognitive Neuroscientist, Clinical Psychologist with more than 15 years’ experience. She focuses on biomarkers and performance indexes within brain-related disorders and how these indices can guide interventions. Previously served as CSO in an international biomedical company where she supervised high-caliber projects that optimize the product development while satisfying key regulatory aspects and clinical validation of the product.
